| 摘要 |
Herpoxin, herpes virus inhibitor consists of two proteins isolated from snake venom of Naja n. kaouthia, which separately and together inhibit the replication of herpes simplex viruses type 1 and type 2 in cell cultures. Herpoxin is characterized as a purified component of snake venom, of the phospholipase A2 (PhA2) enzyme family, which inhibits production of the typical cytopathogenic effects (CPE) produced by herpes viruses type 1 and type 2. Herpoxin consists of two peptides Herp-A and Herp-B having molecular weights 14,000 and 15,000 daltons, respectively, as revealed by gel electrophoresis. The partial sequence for the first fifteen N-terminal amino acids of both Herp-A and Herp-B is: Asn-Leu-Tyr-Gln-Phe-Lys-Asn-Met-Ile-Gln-Cys-Thr-Val-Pro-Asn, which will be referred to as SEQ ID No: 1. The known partial sequences for Herp-A and Herp-B proteins are identical and are typical of phospholipases. However, Herp-A and Herp-B are antigenicaily distinct. Herpoxin is claimed for its method of purification and as a treatment for herpes virus type 1 and type 2 induced oral and genital lesions and other infections. Herpoxin is further claimed as a therapeutic agent for non invasive topical application to treat other viral infections such as: herpes zoster, Kaposi sarcoma in AIDS patents, eczema, etc. It is also an object of this invention to provide Herpoxin as a composition for the treatment of skin infections induced by other microbial agents.
|
